Parkinson’s Disease Dementia
Parkinson’s disease dementia occurs when the cognitive changes that can accompany Parkinson’s become significant enough to interfere with daily life. It typically emerges years after motor symptoms begin, and is distinct from Alzheimer’s disease, though the two can overlap. In ageing populations across East and Southeast Asia, including Japan and South Korea, Parkinson’s disease is increasingly recognised, making awareness of its later-stage complications more important.
Medicine used to treat Parkinson's Disease Dementia
How cognition is affected
The cognitive profile in Parkinson’s disease dementia tends to centre on attention, processing speed, and visual-spatial skills rather than the memory-first pattern seen in Alzheimer’s. People may struggle to concentrate, lose track of conversations, or have difficulty judging distances. Hallucinations and mood disturbances, including depression and anxiety, are also common.
Approaches to managing symptoms
There is no cure, but cognitive symptoms can be moderated. Within neurology, the cholinesterase inhibitor rivastigmine has the strongest evidence base for Parkinson’s disease dementia and is the treatment most widely used. Non-drug strategies, such as structured daily routines, cognitive stimulation, and carer support, complement medical management and help maintain quality of life.